The SERENA-6 trial shows a 54% reduced risk of death with camizestrant, with a median PFS of 16.6 months versus 9.2 months ...

Please provide your email address to receive an email when new articles are posted on . Supportive therapies are necessary to help ensure patients adhere to aromatase inhibitor treatment, according to ...

Treatment with an aromatase inhibitor improves outcomes at 10 years compared to treatment with a SERM in HR+, HER2+ early breast cancer.

EPIK-B5 study evaluated alpelisib plus fulvestrant vs placebo for efficacy and safety in patients with PIK3CA-m HR+, HER2− advanced breast cancer who had progressed on a CDK4/6 inhibitor and an ...

However, long-term experience and specific clinical trials have revealed several limitations of tamoxifen in the adjuvant setting, including limited duration of effectiveness, continuing risk of ...

Photopsia associated with camizestrant was mostly mild, nondisabling, and reversible, according to Adam Brufsky, MD, PhD, at SABCS 2025.

CHICAGO -- Adding investigational capivasertib to fulvestrant extended survival in patients with aromatase inhibitor-resistant estrogen receptor (ER)-positive, HER2-negative advanced breast cancer, ...

Eli Lilly and Co shared updated results of Inluriyo (imlunestrant) from a Phase 3 study in previously treated breast cancer patients.

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset. For patients with hormone receptor ...

Purpose. The clinical and economic benefits of aromatase inhibitor (AI) therapy in early-stage breast cancer are reviewed. Summary. AI therapy has become a standard of care for the treatment of most ...

The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors ...